这是一项 Ib/II 期开放标签研究。剂量递增部分将表征 JDQ443 单药及 JDQ443 与其他研究治疗（TNO155 和 tislelizumab）联合在晚期实体瘤患者中的安全性和耐受性。
适应症：KRAS G12C Mutant Solid Tumors、Carcinoma, Non-Small-Cell Lung、Carcinoma, Colorectal、Cancer of Lung、Cancer of the Lung、Lung Cancer、Neoplasms, Lung、Neoplasms, Pulmonary、Pulmonary Cancer、Pulmonary Neoplasms
入组条件
纳入标准
- Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies
- ECOG Performance Status of 0 or 1
- At least one measurable lesion as defined by RECIST 1.1
- Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion
排除标准
- Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
- Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible
- Clinically significant cardiac disease or risk factors at screening
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。